Designated orphan medicinal Meveol IS product in Europe for the Treatment of cystic fibrosis.
Alaxia Announced That icts drug candidate OSCN / Lactoferrin IT Developer "under the brand name Meveol, WAS Orphan Medicinal Product désigné for the Treatment of cystic fibrosis By The Commission of European Communities on positive opinion froM The European Medicines Agency (EMEA).
Philippe Bordeau, CEO of the company Alaxia said: "This is a" significant step in Developing a Treatment for frequent respiratory infections in patients and Problems Associated With Cystic Fibrosis. The Aim Of Our Company Is To make available to patients as soon as possible an Innovative That has formed of Treatment Proven Effective in vitro and in animals, bacterial strains Including difficulty to address Within CF: Burkholderia cepacia, Pseudomonas aeruginosa mucoid and MRSA. "
About Orphan Medicinal Product designation:
Orphan Medicinal Product Design is Intended to encourage research & the rapid availability of drug / medicinal therapies for patients With rare diseases. After expertise By The European Medicines Agency (EMEA) and In Particular The COMP (Committee of Orphan Medicinal Products) The Most Promising Compounds Have special provisions to Promote and Accelerate Their Development.
Under U.S. guidance, The Design of orphan medicinal product Gives Exclusivity 10 years of potential market in the European Union From The Placing On The Market. Alaxia aussi Benefit From The Expertise Of The EMEA in Optimizing the clinical development of drug candidates icts and participation in The Development of clinical trial protocols.
About Meveol: NCSO / Lactoferrin
Scheduled for administration by inhalation, tea Hypothiocyanite / Lactoferrin (Meveol), Based On Recent Discoveries That highlight a failure of primary immune system in patients With cystic fibrosis. AIMS Meveol product to Compensate for this by Giving Directly To The lungs natural antimicrobial molecules Produced endogenously That Are not Because Of The Disease.
About CF
Cystic Fibrosis Is The MOST common genetic diseases Potentially serious in caucasian populations. It Is Characterized by impaired CFTR Protein That Regulates The Transport of Water and Salt (chloride channel Cl- goal aussi rhodanide channel SNA-) In epithelial cells. The CFTR channel inactivation Of The multiple failures IS Because Of The Immune System of impairing human airways.
Although "significant progress" has been "Made in the management and care, It Is Still Not cured. The average age of death in Europe Is Under 30 Years.
About Alaxia:
Is an innovative company Alaxia Located in The Heart of the pool of pharmaceutical excellence, Lyon France. It AIMS to Develop New Therapeutic Solutions In The context of rare diseases, cystic fibrosis Especially.
Translation Project
